Kinase capable of site-specific phosphorylation of IκBα
AssigneeMillennium Pharmaceuticals, Inc.
InventorZhijian J. Chen
Life of this patent
Estimating the term…
Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorZhijian J. Chen
Estimating the term…
The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of IκBα, IκBα kinase. In particular, the present invention relates to the purified kinase, antibodies having binding affinity specifically to the kinase, and hybridomas containing the antibodies. This invention further relates to bioassays using protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-κB. This invention also relates to ligands, agonists, and antagonists of the kinase, and diagnostic and therapeutic uses thereof. This invention also relates to bioassays using the kinase to identify ligands, agonists, and antagonists. More specifically, this invention relates to selective inhibitors of the kinase.
A purified kinase which phosphorylates IκBα (SEQ ID NO:9) at seine residues 32 and 36, the kinase being a complex of approximately 700 kDa molecular weight as determined by gel filtration chromatography or size exclusion chromatography.
A method for identifying an agonist for the activity of a kinase which phosphorylates IκBα (SEQ ID NO:9) at serine residues 32 and 36, the method comprising:
A method for identifying an antagonist for the activity of a kinase which phosphorylates IκBα (SEQ ID NO:9) at serine residues 32 and 36, the method comprising:
Dependencies are inferred from the claim text.